MANNKIND CORP (MNKD) Stock News
NASDAQ:MNKD - Nasdaq - US56400P7069 - Common Stock - Currency: USD
MNKD Latest News, Press Relases and Analysis
MannKind Corporation to Hold 2025 First Quarter Financial Results Conference Call on May 8, 2025
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), announced today that its first...
Is MannKind Corporation (MNKD) the Best Quality Penny Stock to Buy According to Hedge Funds? (READY TO EDIT2)
We recently published a list of 11 Best Quality Penny Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where MannKind Corporation (NASDAQ:MNKD) stands against other best quality penny stocks. The quality factor in stocks refers to companies with strong fundamentals, financial stability, and reliable performance, […]
LKQ Corporation (NASDAQ:LKQ): En Route to Simplified Business, Better Valuations
We came across a bullish thesis on LKQ Corporation (NASDAQ:LKQ) on ValueInvestorsClub by dman976. In this article, we will summarize the bulls’ thesis on LKQ. The company’s shares were trading at $39.40 when this thesis was published, vs. the closing price of $42.03 on Apr 17. LKQ engages in the distribution of replacement parts, components, […]
Is Shoals Technologies Group, Inc. (SHLS) the Best Quality Penny Stock to Buy According to Hedge Funds?
We recently published a list of 11 Best Quality Penny Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Shoals Technologies Group, Inc. (NASDAQ:SHLS) stands against other best quality penny stocks. The quality factor in stocks refers to companies with strong fundamentals, financial stability, and […]
Is MannKind Corp. (NASDAQ:MNKD) the Best Biotech Penny Stock to Buy According to Hedge Funds?
We recently published a list of the 13 Best Biotech Penny Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where MannKind Corp. (NASDAQ:MNKD) stands against other biotech penny stocks. Peter Marks’s departure from the FDA has left innovators concerned regarding the current state of the […]
Side Gigs With Perks: Get Free Stuff With These 5 Hustles
According to the LinkedIn Workforce Confidence survey, 31% of Americans reported having a side hustle besides their primary job. Read Next: 27 Most Lucrative Side Gigs for People Over 50 Learn More: 5...
MannKind Expands Executive Leadership Team
Dominic Marasco, RPh, joins the company as President, Endocrine Business Unit, effective January 6, 2025 DANBURY, Conn. and WESTLAKE VILLAGE, Calif.,...
MannKind Teams Up with Juncos Hollinger Racing (JHR) Driver Conor Daly to Drive Awareness of Diabetes and Innovative Treatment Options
MANNKIND TEAMS UP WITH JUNCOS HOLLINGER RACING (JHR) DRIVER CONOR DALY TO DRIVE AWARENESS OF DIABETES AND INNOVATIVE TREATMENT OPTIONS...
MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22
MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22...
CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India
CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India...
MannKind to Present at 2024 UBS Healthcare Conference
MannKind to Present at 2024 UBS Healthcare Conference...
MannKind Stock Surges After-Hours On Q4 Revenue Beat, Debt Reduction As Retail Investors Celebrate ‘Amazing Comeback’
The company significantly reduced its debt principal by $236 million, leaving just $36 million in remaining convertible debt, and ended 2024 with $203 million in cash, cash equivalents, and investments.
MannKind (MNKD) Q4 2024 Earnings Call Transcript
MNKD earnings call for the period ending December 31, 2024.
MannKind Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
MANNKIND CORPORATION REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ...
MannKind Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Conference call to provide corporate updates today at 4:30 pm ET
MannKind to Present at Upcoming Investor Conferences
MannKind Expands Executive Leadership Team
MannKind Corporation Announces Exchange of Convertible Notes for Stock and Cash
MANNKIND CORPORATION ANNOUNCES EXCHANGE OF CONVERTIBLE NOTES FOR STOCK AND CASH...
MannKind Corporation Announces Exchange of Convertible Notes for Stock and Cash
MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)
MANNKIND ANNOUNCES SIX-MONTH RESULTS FROM PHASE 3 INHALE-1 PEDIATRIC DIABETES TRIAL UTILIZING INHALED INSULIN (AFREZZA®) ...
CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India
MannKind (MNKD) Q3 2024 Earnings Call Transcript
MNKD earnings call for the period ending September 30, 2024.
MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update
MANNKIND CORPORATION REPORTS 2024 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ...
